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IMPORTANCE The natural history of patients with newly diagnosed high-risk nonmetastatic
(M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care
radiotherapy (RT) is not well documented. Furthermore, no clinical trial has assessed the role
of RT in patients with node-positive (N+) M0 disease. The STAMPEDE Trial includes such
individuals, allowing an exploratory multivariate analysis of the impact of radical RT.
OBJECTIVE To describe survival and the impact on failure-free survival of RT by nodal
involvement in these patients.
DESIGN, SETTING, AND PARTICIPANTS Cohort study using data collected for patients allocated
to the control arm (standard-of-care only) of the STAMPEDE Trial between October 5, 2005,
andMay 1, 2014. Outcomes are presented as hazard ratios (HRs) with 95% CIs derived from
adjusted Coxmodels; survival estimates are reported at 2 and 5 years. Participants were
high-risk, hormone-naive patients with newly diagnosedM0 prostate cancer starting
long-term HT for the first time. Radiotherapy is encouraged in this group, but mandated for
patients with node-negative (N0) M0 disease only since November 2011.
EXPOSURES Long-term HT either alone or with RT, as per local standard. Planned RT use was
recorded at entry.
MAIN OUTCOMES ANDMEASURES Failure-free survival (FFS) and overall survival.
RESULTS A total of 721 men with newly diagnosedM0 disease were included: median age at
entry, 66 (interquartile range [IQR], 61-72) years, median (IQR) prostate-specific antigen level
of 43 (18-88) ng/mL. There were 40 deaths (31 owing to prostate cancer) with 17 months’
median follow-up. Two-year survival was 96% (95% CI, 93%-97%) and 2-year FFS, 77% (95%
CI, 73%-81%). Median (IQR) FFS was 63 (26 to not reached) months. Time to FFS was worse
in patients with N+ disease (HR, 2.02 [95% CI, 1.46-2.81]) than in those with N0 disease.
Failure-free survival outcomes favored planned use of RT for patients with both N0M0 (HR,
0.33 [95% CI, 0.18-0.61]) and N+M0 disease (HR, 0.48 [95% CI, 0.29-0.79]).
CONCLUSIONS AND RELEVANCE Survival for men entering the cohort with high-risk M0
disease was higher than anticipated at study inception. These nonrandomized data were
consistent with previous trials that support routine use of RT with HT in patients with N0M0
disease. Additionally, the data suggest that the benefits of RT extend tomenwith N+M0
disease.
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T he STAMPEDETrial (MRC PR08, CRUK/06/019) has re-cruited men starting first-line long-term hormonetherapy (HT) for the first time for prostate cancer with
or without metastases. The STAMPEDE population therefore
includes a cohort of men with newly diagnosed nonmeta-
static (M0)disease that iseitherhighrisk localizedornodeposi-
tive (N+); approximately 40%of trial entrants have nometas-
tases. The trial uses amultiarm,multistage design to test the
addition of further treatments to HT-based therapy, includ-
ing docetaxel, zoledronic acid, celecoxib, abiraterone ac-
etate, enzalutamide, and, only in patients with newly diag-
nosed metastatic (M1) disease, local radiotherapy (RT).
Research arms have recruited at overlapping times, but,
throughout, the control arm has consistently been use of HT,
with RT where appropriate.1-8
This articledescribes theprognosis formenwithnewlydi-
agnosed, high-riskM0disease, split bynodal involvement, to
complement the outcomes thatwehave reported for patients
withmetastaticdiseaseallocatedto thecontrolarmof the trial.7
Wealso considered the effect of radical RTon time toprogres-
sion, bynodal involvement.Adetailedunderstandingof these
effectswill underpin the interpretationof the trial’s compara-
tive outcomes as the study matures.
There is limited information on the natural history of pa-
tientswithnewlydiagnosed, high-riskM0prostate cancer re-
ceiving androgen deprivation therapy (ADT) either alone or
withRT. Since the trial commenced, 2 large randomized clini-
cal trials, SPCG-79 andPR07,10have shown thatRT to thepros-
tatewithorwithout thepelvis, in addition toADT, reduces risk
of prostate cancer death by approximately 50%; both studies
havemore limitedpopulations thanSTAMPEDE.First, SPCG-7
was exclusively in node-negative (N0) disease and largely at
the lower end of the risk spectrum (maximum prostate-
specific antigen [PSA] level, 80 ng/mL, but median PSA, ap-
proximately 20ng/mL). Second, PR07didnotmandate nodal
staging but was only for N0 disease if staging had been per-
formed; the trial had no PSA level cap. Therefore, there re-
mainsuncertainty about the role ofRT inmenwithN0M0dis-
ease and higher PSA levels, and in men with N+M0 disease.
To date, no randomized clinical trials have looked at the role
of RT in patients with N+M0 disease, and to our knowledge
none are planned. The STAMPEDETrial has recruited and ob-
served many such patients.
WhenSTAMPEDEstarted,patientswithN0M0diseasehad
the option of RT with HT. Radiotherapy was to be given ap-
proximately 6 to 9 months after randomization, to allow ad-
equate time for hormone response and avoid combination of
RT anddocetaxel for relevant patients. StartingNovember 15,
2011,RTbecamemandatory for thisnode-negativepatient sub-
set on the basis of the SPCG-7 and PR07 trial reports. For pa-
tientswithN+M0disease, RT (also after 6-9months) has been
optional throughout.
The intendeduse of RT is a stratification factor at trial en-
try. The trial control armprovides a suitable cohort, with pro-
spectively collected data in which to undertake an explor-
atory multivariate analysis to opportunistically investigate
possible impact of radical RT in patients with these disease
characteristics at entry, in particular, N0, high PSA level, and
N+, inanonrandomized fashion.Wehypothesized thatRTwas
associated with better prognosis inmenwithM0 disease, re-
gardless of nodal involvement.
Methods
Overall Trial Recruitment and Eligibility
Patients joined the STAMPEDETrial frommore than 100 sites
across theUnitedKingdomandSwitzerland.Tobeeligible, pa-
tientsmusthaveprostatecancer thatwaseitherhigh-risknewly
diagnosedN0M0disease, newly diagnosedM1 orN+disease,
or disease (previously treatedwith radical surgery and/or RT)
that was relapsing at the time of randomization. All patients
were intended for first-line treatment with long-term HT for
the first time, and this must have started no longer than 12
weeks prior to randomization. Baseline investigations must
have been completed prior to randomization, which in-
cludedcomputed tomographyormagnetic resonance imaging
(MRI) of thepelvis and abdomen; bone scanor equivalent, for
example, whole-body MRI; chest x-ray if chest was not in-
cluded in the computed tomography or MRI; electrocardio-
gram; and PSA test. There were no age restrictions; patients
had to be fit for chemotherapy andhaveno significant cardio-
vascular history.
Study Population
For this cohort analysis, we selected men with newly diag-
nosed prostate cancer, which we defined as being diagnosed
within 6 months prior to randomization, that was nonmeta-
static, and who were randomized to the control arm of the
STAMPEDETrial betweenOctober 2005andMay2014.All pa-
tients were planned for treatment with standard-of-care HT,
according to local practice, which comprised either orchiec-
tomy or use of luteinizing hormone–releasing hormone ago-
nists or antagonists with or without long-term oral anti-
androgens. Hormone therapy was to continue for at least 2
yearsoruntil diseaseprogression.Treatmentafter thesepoints
was at thediscretionof the consulting clinician.We furtherdi-
vided this cohort to investigate the effects ofRT: formenwith
At a Glance
• This research describes the prognosis of men with newly
diagnosed, nonmetastatic (M0) prostate cancer and considers
the effect of radiotherapy on failure-free survival by nodal
involvement (N0 vs N+).
• We hypothesized that radiotherapy was associated with better
prognosis in menwith M0 prostate cancer, regardless of nodal
involvement.
• Survival for men with high-risk M0 disease was higher than
anticipated at study inception, with 80% still alive at 5 years.
• Failure-free survival outcomes favored planned use of
radiotherapy for patients with both N0M0 (hazard ratio, 0.33
[95% CI, 0.18-0.61]; consistent with previous reported
randomized trials) and N+M0 disease (hazard ratio, 0.48 [95%
CI, 0.29-0.79]).
• Radiotherapy was tolerable and the toxic effects profile was as
expected.
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N0M0diseasewe selected those randomizedprior toNovem-
ber 15, 2011, afterwhichRTbecamecompulsory for this group
(the “N0M0 subcohort”); and for patients with N+M0 dis-
ease, for whom RT remains optional, we selected men ran-
domizedat least 12monthsbefore thedata cutoff ofMay2014,
to ensure sufficient follow-up (the “N+M0 subcohort”).
Data Collection
Baseline data included patient demographic characteristics,
regional lymph node status, Gleason sum score, World
Health Organization (WHO) performance status, pre-HT PSA
level, and planned RT. Details of disease progression were
obtained from progression forms. Details of reported RT
were obtained from the RT (detail) form. The protocol can be
found at http://www.stampedetrial.org. The trial was regis-
tered as NCT00268476 and ISRCTN78818544 and had the
relevant regulatory approval, national ethics approval, and
local practical site approval. All patients gave written,
informed consent.
Radiotherapy Techniques
ExactRT techniquewas at site discretion.Guidancewas given
within the trial protocol (section 6.15) such that for patients
with negative nodes on axial imaging, clinicians may choose
between irradiating prostate and seminal vesicles alone or in-
cludepelvicnodes.Additional stagingtests, suchaspelvicnode
sampling, may aid decision making. Conformal or intensity-
modulated radiotherapy (IMRT) should be used in all pa-
tients.Where patients have good clinical evidence that nodes
are tumor free or where nodal radiotherapy is contraindi-
cated (eg, significant bowel disease), treatmentmay be given
to the prostate gland and seminal vesicles only. Recom-
mendeddosing is74Gy in37 fractions to theprostateandsemi-
nal vesicles or the equivalent using hypofractionated sched-
ules, with optional pelvic node dose of 46 to 50 Gy in 2-Gy
fractions or equivalent; suggested dose is 55 Gy in 37 frac-
tions with IMRT. Higher doses may be considered if the de-
partment is experienced at using IMRT for nodal RT. No for-
mal lymph node size was given to define normality/
abnormality, but generally an upper limit of normality of 10
mmisused11; formostpelvic lymphnodesites8mmis thecut-
off used. Conventionally anupper limit of 10mmin short axis
dimension is used to define normal size lymph node.
OutcomeMeasures
The trial’s definitive and intermediate primary outcomemea-
sures were overall survival and failure-free survival (FFS),
respectively.12 These outcomemeasures formed the primary
focusof this cohort analysis. Survivalwasdefinedas time from
randomization to death from any cause. Failure-free survival
was defined as time from randomization to the first of the fol-
lowing events: biochemical failure (as defined herein); pro-
gression either locally, in lymph nodes, or in distantmetasta-
ses; or death from prostate cancer.
Biochemical failure, based on the PSAnadir in the first 24
weeks after randomization, was defined as:
1. 50%abovenadir andat least4ng/mLifPSAnadir is less than
4 ng/mL;
2. 50% above nadir if PSA nadir is at least 50% lower than
the last pretreatment PSA but remaining greater than
4 ng/mL; or
3. Failure at time zero if PSA nadir is greater than 50% of the
last pretreatment PSA level.
Cause of death was determined by central review with-
out reference to the allocated treatment. Death was taken as
being fromprostate cancerwhen classified by the reviewer as
“definitely” or “probably” prostate cancer. The site investiga-
tor’s determination was used for deaths not yet reviewed.
Statistical Analyses
These analyses are nonrandomized and post hoc. Analyses
were performed using Stata, version 13, using standard sur-
vival analysismethods. Kaplan-Meier estimateswere used to
produce survival curves. Cox models were used to investi-
gateeffectsbysubgroup;modelswereadjusted for initialGlea-
son sum score category (≤7, ≥8, unknown), log-transformed
pre-ADT PSA level, age at randomization (<60, 60-64, 65-69,
≥70years), andWHOperformance status (0vs 1-2) at random-
ization.Medianfollow-upwasdeterminedthroughreversecen-
soring on death.
Themain time-to-event analyseswere calculated as time
fromrandomization to theoutcomeof interest,with thosenot
experiencing the event being censored at the time of last con-
tact. The analyses of reported RT use employed a landmark
approach,13,14 inwhichanalyseswere timed from6months af-
ter randomization, to allow forRT to be started. Patientswere
included in the landmark analysis if they had follow-up 6
months fromrandomizationandhadnot experienced theout-
come of interest within the first 6months; patients with pro-
gression, death, or withdrawal of consent prior to 6 months,
or less than6-months’ follow-up reported,were therefore ex-
cluded from the landmark analysis.
Outcomes were considered according to the following
groupings: presenceof regional lymphnode involvement (N0
vs N+), year of randomization, and both planned and re-
ported radical RT. Radiotherapy schedules were grouped ac-
cording to field and fractionation (conventional or hypofrac-
tionated).
Results
Patient Cohort
Figure 1 shows the cohort selection process. Of 5573 eligible
patients randomized to the trial from October 5, 2005, to
May 1, 2014, 1858 were allocated to the control arm. Of these,
721 (13% of all randomized men) had nonmetastatic prostate
cancer, newly diagnosed within 6 months prior to random-
ization, and were included in the main analytic cohort. The
data set was frozen in May 2014, with median (interquartile
range [IQR]) follow-up of 17 (6-36) months in this cohort, and
1380.5 patient-years total follow-up. From these, 357 of 721
(50%) patients met our time criteria for inclusion in the “RT
analyses.” Table 1 shows the baseline characteristics of the
whole M0 cohort and the N0 and N+ subcohorts, split by
planned RT status.
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Survival and Failure-Free Survival
Outcomes—Full M0 Cohort
eFigure 1 in the Supplement shows overall survival and FFS
for all 721 patients. Forty of 721 had died; 31 of 40 (78%)
deaths were attributed to prostate cancer. Two-year survival
was 96% (95% CI, 93%-97%), with 80% (95% CI, 72%-86%)
still alive at 5 years. One hundred fifty-one of 721 reported at
least 1 FFS event, with 81% (123 of 151) reporting PSA failure
only as their first FFS event. Median (IQR) FFS was 63 (26 to
not reached) months; 2-year FFS was 77% (95% CI, 73%-
81%). Failure-free survival was worse in patients reporting
nodal involvement at randomization, with 27% of patients
with N+ disease reporting an event compared with 17% of
patients with N0 disease (HR, 2.02 [95% CI, 1.46-2.81]).
Five-year FFS for patients with N+ disease was 47% (95% CI,
36%-58%), compared with 60% (95% CI, 50%-68%)
for patients with N0M0 disease. There was no evidence of
a difference in FFS by year of randomization (likelihood
ratio test P = .88); there were insufficient data yet to explore
survival.
Figure 1. Cohort Selection for Full M0 Cohort and Patient Selection for the Radiotherapy Analysis, in N0M0 andN+M0 Subcohorts
5573 Patients randomized between
October 5, 2005, and May 1, 2014
1858 Allocated to control arm
3715 Allocated to research arms
1137 Excluded
1090 (59%) Patients with metastatic disease
47 Previously treated or prostate
cancer diagnosed more than 6 mo
before randomization
434 Patients with N0 disease
180 Patients in the N0M0 subcohort
107 RT reported 14 RT not reported 18 RT reported 41 RT not reported
121 RT planned 59 RT not planned
125 Patients in the N0M0
subcohort who
reported RT
121 Included in
landmark analysis
55 Patients in the N0M0
subcohort who did
not report RT
254 Excluded
254 Randomized after
November 15, 2011
721 Patients included with nonmetastatic
disease diagnosed within 6 mo before
randomization
46 Included in
landmark analysis
9 Excluded
7 Early progression
2 <6 mo follow-up
4 Excluded
2 Early progression
1 <6 mo follow-up
1 Palliative dose
286 Patients with N+ disease
177 Patients in the N+M0 subcohort
68 RT reported 29 RT not reported 10 RT reported 70 RT not reported
97 RT planned 80 RT not planned
78 Patients in the N+M0
subcohort who
reported RT
71 Included in
landmark analysis
99 Patients in the N+M0
subcohort who did
not report RT
109 Excluded
109 Randomized <1 y
before data freeze
86 Included in
landmark analysis
13 Excluded
11 Early
 progression
2 <6 mo
follow-up
7 Excluded
7 Early progression
1 Excluded
1 Nodal stage unknown
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Of 151 patients with an FFS event, there were 33 deaths
withmedian (IQR) 18 (7-37)months’ follow-up fromFFSevent.
Median survival from FFS event was not reached; however,
74% (95% CI, 63%-82%) were still alive 2 years after first FFS
event, with 51% (95% CI, 32%-66%) alive at 5 years.
Impact of Radiotherapy on Failure-Free Survival
Figure 2 shows time from 6-month landmark to FFS by re-
ported radical RT status, split by time-specified nodal status
at baseline.
N0M0 Subcohort
Therewere 180patientswithN0M0disease randomizedprior
toNovember 15, 2011. Two-year survival in thisN0M0subco-
hort was 97% (95% CI, 93%-99%), with 84% (95% CI, 74%-
91%) still alive after 5 years.
Figure 1 showsthemenplannedforandreceivingRT.Four-
teen of 121 (12%) did not report receiving their planned RT: 2
experienceddisease progressionwithin 6months of random-
ization, and 12 had no RT data. Median (IQR) time to starting
RTwas 5.8 (4.5-6.9)months fromrandomization (eFigure 2 in
the Supplement).
Failure-free survival was better among patients planned
for radicalRTagainst thosenotplanned,withadjustedHR,0.33
(95% CI, 0.18-0.61). Two-year FFS was 93% (95% CI, 87%-
97%) in patients planned for RT comparedwith 68% (95%CI,
54%-78%) of patients not planned for RT (eFigure 3A in the
Supplement).
The exploratory landmark analysis (selection inFigure 1),
timed from 6 months after randomization, compared pa-
tientswho receivedRTagainst thosenot reportingRT (regard-
less of planned use). A total of 167 patients were failure free
and uncensored at 6months, so included in this analysis, 121
receivingRTand46not reportingRT.Failure-free survivalwas
better with received RT: adjusted HR, 0.25 (95% CI, 0.13-
0.49) with 2-year FFS of 96% (95% CI, 90%-98%) in patients
receiving RT comparedwith 73% (95%CI, 57%-84%) in those
not reporting RT (Figure 2A).
N+M0 Subcohort
There were 177 patients with N+M0 disease randomized at
least 1 year prior to the data freeze. Two-year survival in this
N+M0 subcohort was 93% (95% CI, 88%-96%), with 71%
(95% CI, 56%-82%) still alive after 5 years. Figure 1 shows
the patients planned for and receiving RT. Twenty-nine of 97
patients planned for RT did not report receiving it: 5 experi-
enced disease progression within 6 months after randomiza-
tion, and 24 had no RT data. Median (IQR) time to starting
RT was 6.1 (4.7-8.5) months from randomization (eFigure 2
in the Supplement).
Table 1. Patient Characteristics at Baseline, Overall, and in N0M0 andN+M0 Subcohorts
Randomized Patient
Characteristic
No. (%)a
Full M0 Cohort
October 5, 2005,
to May 1, 2014
(N = 721)
Radiotherapy
N0M0 Subcohort
Before November 15, 2011
N+M0 Subcohort
at Least 1 Year
Before Data Freeze
None Planned
(n = 59)
Planned
(n = 121)
None Planned
(n = 80)
Planned
(n = 97)
Age group, y
<60 133 (19) 13 (22) 31 (26) 17 (21) 21 (22)
60-64 145 (20) 10 (17) 26 (21) 22 (28) 27 (28)
65-69 189 (26) 11 (19) 34 (28) 16 (20) 30 (31)
≥70 254 (35) 25 (42) 30 (25) 25 (31) 19 (20)
Age at randomization,
median (IQR), y
66 (61-72) 68 (61-73) 65 (59-69) 65 (60-71) 65 (60-68)
Gleason Sum Score
<8 156 (22) 15 (25) 29 (24) 21 (26) 18 (19)
≥8 535 (74) 44 (75) 91 (75) 56 (70) 76 (78)
Unknown 30 (4) 0 1 (1) 3 (4) 3 (3)
World Health Organization
performance status
0 611 (85) 47 (80) 114 (94) 69 (86) 85 (88)
≥1 110 (15) 12 (20) 7 (6) 11 (14) 12 (12)
Nodal stage
N0 434 (60) 59 (100) 121 (100) 0 0
N+ 286 (40) 0 0 80 (100) 97 (100)
NX 1 (0.1) 0 0 0 0
PSA before ADT,
median (IQR)
ng/mL 43 (18-88) 90 (58-164) 45 (22-75) 40 (17-98) 28 (15-67)
Log-transformed 3.8 (2.9-4.5) 4.5 (4.1-5.1) 3.8 (3.1-4.3) 3.7 (2.8-4.6) 3.3 (2.7-4.2)
Abbreviations: ADT, androgen
deprivation therapy; IQR, interquartile
range;M0, nonmetastatic;
M1,metastatic; N+, node positive;
N0, node negative;
PSA, prostate-specific antigen;
RT, radiotherapy.
a Data are reported as number
(percentage) unless otherwise
specified. Percentages may not total
100% because of rounding.
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Failure-free survival was better among those planned for
radical RT than those not planned: adjusted HR, 0.48 (95%
CI, 0.29-0.79), with 2-year FFS of 81% (95% CI, 71%-87%)
and 53% (95% CI, 40%-65%), respectively (eFigure 3B in the
Supplement).
A total of 157 patients were event free and uncensored at
6 months and included in the landmark analysis by reported
RT (regardless of planned use). Failure-free survival was bet-
ter among patients receiving RT: adjusted HR, 0.35 (95% CI,
0.19-0.65),with2-yearFFSof89%(95%CI,77%-94%)and64%
(95% CI, 51%-75%), respectively (Figure 2B).
Radiotherapy Field and Fractionation
Reported RT is summarized for the subcohorts in Table 2. For
the71patientswithN+M0disease, kept in the landmarkanaly-
sis and reporting RT, 82% (58 of 71) reported receiving RT to
both prostate and pelvis, with conventional fractionation for
all but8patients. For the 121patientswithN0M0disease, kept
in the landmark analysis and reporting RT, 43% (52 of 121) re-
ceivedRT to bothprostate andpelvis,with conventional frac-
tionation for all but 14 patients.
Reported Radiation Therapy Oncology Group
Late Toxic Effects
Table 2 also shows adverse effects associated with radical RT,
using Radiation Therapy Oncology Group late toxic effect
grading, for all patients receiving RT, split by nodal subco-
horts. Reported adverse effects were similar for patients with
and without nodal involvement, with no grade 4 or 5 adverse
effects reported.
Discussion
We selected a cohort ofmenwith nonmetastatic, newly diag-
nosed, hormone-naive prostate cancer, at high risk of dying
from the disease, whowere treatedwith long-termADTwith
orwithoutRT.We foundmedianFFS of 63months for the full
M0cohort, fromstudy entry. Two-year FFS and survivalwere
77%and96%, respectively, and80%were still alive at 5 years.
We report a clear improvement in FFS with RT.
Comparisons with other published series must be made
with caution because of differences in case mix and the start
timeof estimate (Table 3). TheGETUG-12 trial, comparingADT
+RT(74Gy in37 fractions)withorwithout4cyclesofdocetaxel
andestramustine in ahigh-risknonmetastatic population, re-
cently reported results in its control arm and showed 5-year
relapse-free survival of approximately 80%; this is an obvi-
ously different patient group from the STAMPEDE control
arm.17 Older RT series focused on generally lower-risk N0M0
cases, for example, GETUG-01,16 which examined the role of
nodalRT inpatientswith clinically node-negativedisease and
which had only approximately 11%Gleason score 8 or greater
and 25% T3 tumors (in comparison with our population in
Table 1). Nonetheless, median FFS reported here is compa-
rable to median PFS reported for the higher-risk subgroup in
GETUG-01, with similar progression criteria.
The standard-of-care therapy for the STAMPEDE control
armwas initially envisaged as ADT alone. When the trial was
launched in October 2005, a decisionwasmade to permit RT
at the individual investigator’s discretion and to stratify by in-
tended RT use. Guidelines on RT doses and volumeswere in-
cluded in the protocol in an attempt to standardize practice.
Despitepublicationof SPCG-7 in2009,9 theproportionofmen
with N0M0 disease being offered RT within the trial re-
mainedstableatapproximately60%.WithpublicationofPR07
in 2011,18 the trial management group took the positive deci-
sion to mandate RT in this subgroup to ensure that the trial
standardof carewasupdated to reflect thenewevidencebase.
Within the N0M0 and N+M0 subcohorts, both planned
and reported radical RT was associated with prolonged FFS,
even after adjustment for initial Gleason sum score category,
log-transformed pre-HT PSA level, age at randomization, and
WHO performance status at randomization. Multivariate HRs
for FFS, both by stated RT intention (HR, 0.33 [95% CI, 0.18-
0.61]) and landmark analysis (HR, 0.25 [95% CI, 0.13-0.49]),
Figure 2. Failure-Free Survival for Reported Radical Radiotherapy Status, in N0M0 andN+M0 Subcohorts
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are reassuringly consistent with corresponding data in PR07
(HR, 0.31 [95% CI, 0.25-0.39]) and SPCG-7 (PSA recurrence-
only: HR, 0.16 [95% CI, 0.12-0.20]).
It is thusof interest that theHR forFFS forRT in theN+M0
subcohort is also strongly in favor of RT, in both RT intention
(HR, 0.48 [95%CI, 0.29-0.79]) and reported RT use (HR, 0.35
[95%CI,0.19-0.65]).Previouswidespreadconcerns thatRTwas
inappropriate in patients with high-risk nonmetastatic dis-
ease, due to high probability of occult metastases, thus ap-
pear to bemisplaced, althoughRTcould act by anabscopal ef-
fect. We are testing this latter hypothesis in patients with
metastatic disease within STAMPEDE.19 In addition, the re-
ported late RT adverse event toxicity profile appears similar
for patients with N0 andN+ disease, in keepingwith recently
published modern RT series that include GETUG-01 and
PR07.10,16
Within theN+M0group, thereare still no randomizeddata
on the role of radical RT, andwe are not aware of any ongoing
trials.However, thedatapresentedhere showa substantial ef-
fectofRTonFFS, consistentwith that seen in thepatientswith
N0M0 disease within the same data set, and also the pub-
lished randomized data in patients with N0M0 disease. It is
thus plausible that a similar benefit for RT, as seen in patients
withN0disease, exists forpatientswithN+M0diseaseaswell.
Table 2 lists the RT fractionation to prostate and seminal
vesicles and to lymph nodes. As expected, few patients with
N+disease receivedprostate-onlyRT,whereas inclusionof the
pelvis in RT to patients with N0 disease was in less than half
of the patients.
Thedatapresentedhere are further consistentwith the re-
cent study published using retrospective, observational data
Table 2. Reported Radiotherapy Field and Fractionation, andWorst
Reported Radiation Therapy Oncology Group (RTOG) Late Toxic Effects
Grading for Those Landmark Patients Reporting Radiotherapy, in N0M0
andN+M0 Subcohorts
Reported Radiotherapy Details
Subcohort, No. (%)
N0M0
(n = 121)
N+M0
(n = 71)
Radiotherapy Prostate Fractionationa
Hypofractionated
Prostate only 13 (11) 5 (7)
Prostate and pelvis 1 (1) 3 (4)
Conventionally fractionated
Prostate only 56 (46) 8 (11)
Prostate and pelvis 51 (42) 55 (78)
Missing 0 0
RTOG Late Adverse Effect and Gradeb
Diarrhea
0 90 (79) 48 (78)
1 19 (17) 10 (16)
2 4 (3) 4 (6)
3 1 (1) 0
Missing 7 9
Proctitis
0 94 (82) 53 (86)
1 10 (9) 4 (6)
2 8 (7) 5 (8)
3 2 (2) 0
Missing 7 9
Cystitis
0 109 (96) 55 (89)
1 2 (2) 4 (6)
2 2 (2) 3 (5)
3 1 (1) 0
Missing 7 9
Hematuria
0 108 (95) 58 (94)
1 2 (2) 2 (3)
2 3 (3) 1 (2)
3 1 (1) 1 (2)
Missing 7 9
Rectal-anal stricture
0 114 (100) 62 (100)
1 0 0
2 0 0
3 0 0
Missing 7 9
(continued)
Table 2. Reported Radiotherapy Field and Fractionation, andWorst
Reported Radiation Therapy Oncology Group (RTOG) Late Toxic Effects
Grading for Those Landmark Patients Reporting Radiotherapy, in N0M0
andN+M0 Subcohorts (continued)
Reported Radiotherapy Details
Subcohort, No. (%)
N0M0
(n = 121)
N+M0
(n = 71)
Urethral stricture
0 113 (99) 62 (100)
1 1 (1) 0
2 0 0
3 0 0
Missing 7 9
Rectal ulcer
0 112 (98) 62 (100)
1 1 (1) 0
2 0 0
3 1 (1) 0
Missing 7 9
Bowel obstruction
0 114 (100) 62 (100)
1 1 (1) 0
2 0 0
3 0 0
Missing 7 9
Abbreviations: M0, nonmetastatic; M1, metastatic; N+, node positive; N0, node
negative.
a Hypofractionated dose is defined as greater than 2 Gy per fraction.
Conventionally fractionated dose is defined as 2 Gy or less per fraction.
b The purpose of the second part of this table is to indicate the long-term toxic
effects; it is not to facilitate comparisons of toxic effects across the subgroups.
Note that all patients in the N0M0 cohort had been in the trial for at least 2.5 y
by the time of the data freeze; the patients in the N+M0 cohort had been in
the trial for at least 1 y. No patients reported grade 4 or 5 RTOG toxic effects.
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from the US National Cancer Data Base, which reported data
onmen who received a diagnosis between 2004 and 2006.15
Using propensity-score matching in approximately 600 pa-
tients with cN+M0 prostate cancer, they reported an advan-
tage in overall survival.
STAMPEDEisnowcollecting randomizeddataonthevalue
of prostateRT inpatientswithnewlydiagnoseddistantmeta-
static disease at the timeof trial entry.8,19Approximately 1800
patientswill contribute to this randomizedcomparison,which
targets a relative improvement inoverall survival of 25%;more
than 1300 patients have already been randomized. If the re-
sults are positive, this will be likely to help further elucidate
the data for the N+M0 setting.
Themain strengths of our cohort include the fact that pa-
tients were from multiple centers and that data were col-
lected in a consistent, prospective fashion.However, there are
limitations. First, our substantive cohort was drawn from the
control armof a clinical trial, inevitably applying eligibility re-
strictions. Second, this is not a formally planned, random-
izedcomparisonandsonumbers are small, and thereare likely
tobeunmeasuredconfoundersnot accounted for in theanaly-
ses and potentially important differences in baseline charac-
teristicsbecauseonlymenwhowereconsidered fit forRTwere
planned for RT anddefinitions of fitness for RTmayhave var-
ied by site. We thereforemight expect men planned for RT to
have better prognosis than men not planned for RT, and the
treatment effect seen here to be an overestimate of the ben-
efit, but the consistency of effect with those previously pub-
lished randomized trials enforces confidence in there being a
positive effect of RT. Third, median follow-up within this co-
hort is only 17months and survival data are still immature; re-
cruitmentwasongoingwhenthisdatasetwas frozen,withonly
40deaths in total (16 in theN0M0 subcohort, 22 in theN+M0
subcohort, and2 inpatients not included in the analyzed sub-
cohorts).
Although using data from a trial’s control arm invariably
has limitations, there is need for a randomized clinical trial
within the N+M0 population to address questions prospec-
tively. No such trial has reported or is planned to report, and
construction of one would be at great financial cost while
taking many years to provide reliable long-term data. The
control arm of a high recruiting trial, such as STAMPEDE,
therefore makes efficient use of the wealth of data collected
for the trial while incurring no extensive additional costs and
simultaneously providing treatment safety and efficacy
answers. Also, as highlighted herein, there is reassurance in
the fact that the results we present for the N0M0 subcohort
are consistent with those presented for similar patients in
both PR07 and SPCG-7; this gives us confidence in the
results for the N+M0 subcohort. Such results, along with the
ever-evolving accuracy of RT imaging tools, present an
important contribution to the treatment of men with locally
advanced prostate cancer. We show here that a combination
of both early ADT and RT, in suitable men, is effective in
delaying time to first relapse, as well as being tolerable in
terms of acute toxicity.20-24
Table 3. Results in ContextWith Data FromPreviously Published Studies
Source Data Type Population
Deaths, No./
Patients, No.
Radiotherapy
Effect, HR
(95% CI)a
Treatment
Groups
Estimates
Progression Survival
Comparative Data
SPCG-7,9 2009 R Low risk, N0M0 116/875 0.16 (0.12-0.20) ADT only 10-y PSA-FS, 25% 10-y OS, 61%
ADT+RT 10-y PSA-FS, 74% 10-y OS, 70%
NCIC PR.3/MRC
PR07,10 2011/2015b
R N0M0 465/1205 0.31 (0.25-0.39) ADT only 10-y PFS, 46% 10-y OS, 49%
ADT+RT 10-y PFS, 74% 10-y OS, 55%
National Cancer
Database,15 2015
NR High-risk M0 ?/636c 0.50 (0.37-0.67) ADT only Not given 5-y OS, 53%
ADT+RT Not given 5-y OS, 72%
STAMPEDE, 2015c NR N0M0 16/180 0.25 (0.13-0.49) ADT only 5-y FFS, 38% 5-y OS, 86%
ADT+RT 5-y FFS, 76% 5-y OS, 90%
STAMPEDE, 2015d NR N+M0 22/177 0.35 (0.19-0.65) ADT only 5-y FFS, 39% 5-y OS, 82%
ADT+RT 5-y FFS, 65% 5-y OS, 82%
Reference Data
GETUG-01,16 2007 R N0M0 36/352 Not relevant RT to
pelvis + prostate
5-y PFS, 66% 5-y OS, 87%
RT to prostate
only
5-y PFS, 65% 5-y OS, 88%
GETUG-12,17 2015 NR High-risk M0 49/206 Not relevant ADT with or
without RT
8-y RFS, ~50% 8-y OS, ~83%
STAMPEDE, 2015d NR Newly diagnosed
M0
40/721 Not relevant ADT with or
without RT
5-y FFS, 55% 5-y OS, 80%
Abbreviations: FFS, failure-free survival; HR, hazard ratio; M0, nonmetastatic;
N+, node positive; N0, node negative; NR, nonrandomized; OS, overall survival;
PFS, progression-free survival; R, randomized; RT, radiotherapy.
a Effect on progression unless otherwise stated.
b PR07 had nomandatory nodal staging.
c Patients matched by propensity scoring; number of deaths unknown; no
analysis on progression.
dData presented within this article.
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Conclusions
Survival outcomes in this cohort of men with nonmeta-
static, newly diagnosed disease were shown to be good,
with time to progression increased by RT to the prostate
with or without the pelvis, for patients both with and with-
out nodal involvement. The data presented support routine
use of RT in patients with N+ nonmetastatic prostate can-
cer. Investigators and funders should be aware that this
improved survival may delay results in ongoing clinical
trials.
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Invited Commentary
Pelvis Plus Prostate Radiation Therapy and the Risk of Death
inMenWith Newly Diagnosed Node-Positive Prostate Cancer
Anthony V. D’Amico, MD, PhD
Both single-institutional retrospective series and a multi-
institutional observational study1,2 find a significant associa-
tion between a reduced risk of death and treatment of node-
positiveprostatecancerusing
both external-beam radia-
tion treatment (EBRT) of the
prostate and pelvic lymph
nodes (LNs) and androgen deprivation therapy (ADT) com-
pared with ADT alone. However, whether this association is
causal remains unanswered and requires testing in aprospec-
tive randomized trial. In this issue of JAMA Oncology, James
and colleagues3 use data from the control arm in the Sys-
temic Therapy in Advancing or Metastatic Prostate Cancer:
Evaluation of Drug Efficacy (STAMPEDE) Trial to investigate
this issue.
Specifically, they perform a Cox regressionmultivariable
analysis4 evaluating the riskof failure-free survivalwhere fail-
ure is defined as prostate-specific antigen (PSA) level; local,
regional, or distant treatment failure; or death from prostate
cancer, adjusting forhighest initialGleason score category (≤7,
≥8, unknown), log-transformed pre-ADT PSA level (continu-
ous), age (<60, 60-64, 65-69, ≥70years), andWorldHealthOr-
ganization performance status (0 vs 1 or 2) at randomization.
Among 177 men with node-positive prostate cancer, 97 were
planned for EBRT and 68 of these, plus 10men not originally
slated for EBRT,were recordedashaving receivedEBRT to the
prostate with or without pelvic LNs. After a median fol-
low-up of 17months in the overall study cohort, 20menwith
node-positiveprostate cancer experienceda failure event.The
authors report that both planned and delivered prostatewith
orwithoutpelvicEBRTwasassociatedwith reducedriskof fail-
ure, with adjusted hazard ratios of 0.48 (95% CI, 0.29-0.79)
and 0.35 (95% CI, 0.19-0.65), respectively.
There are several reasons to interpret these results with
caution. First, as the authors note, EBRT use was prescribed
by physician choice and therefore nonrandomized. In addi-
tion, the short median follow-up of 17 months in a study in
which at least 2 years of ADTwas required and a primary end
point (ie, failure-free survival) that is likely driven by PSA-
related failureeventsat this shortmedian follow-up timemake
it difficult topredictwhat effect a reduction inmostlyPSA fail-
ure–free survivalwill haveonoverall survival.Moreover, given
the lowevent rate (20of 177 [11.3%]), theauthorswerenot able
to analyze overall survival as an end point or adjust for all
knownprostate cancer prognostic factors in theirmodel, such
as tumor category, tertiary grade 5 inmenwith Gleason score
7prostate cancer, andpercent positive biopsies. Also,with40
deaths in the overall study cohort of which 9 could not be at-
tributed to prostate cancer, a competing risk5 and not Cox re-
gression analysis4 would have beenmore appropriate to ana-
lyze the end point of time to first failure or prostate cancer
death. Finally, treatment use varied, in that somemen could
have received irreversible and life-long testosterone suppres-
sion via bilateral orchiectomy as comparedwith 2 years of re-
versible ADT using a luteinizing hormone–releasing hor-
moneagonist.Moreover, inmen inwhomEBRTwasdelivered,
the prostate was always treated whereas the pelvic LNs were
only treated in a subset and thedose fractionation scheme for
EBRTdeliveryvaried.Both thevariations inEBRTandADTcan
affect time to first failure. Ideally, to account for these varia-
tions in treatment an adjustment in the model using a treat-
ment propensity score would have been used, but the short
median follow-up and consequently a low event rate would
likelynotpermit the inclusionof thetreatmentpropensityscore
and other known prostate cancer prognostic factors without
running the risk of overfitting the model.
Given these limitations, the conclusion that the addition
of prostate and pelvic EBRT to ADT in the treatment of node-
positiveprostate cancer reduces the riskof failure,whileprob-
ably true, cannot be rigorously concluded from the present
analysisbecauseof theshortmedian follow-up, lowevent rate,
nonrandomized data, and lack of adjustment for treatment
variation and some known prostate cancer prognostic fac-
tors. Moreover, to affect clinical practice, at a minimum one
should provide evidence in amodel powered for survival and
adjusted for age, comorbidity, known prostate cancer prog-
nostic factors, and type and duration of ADT that treatment
using both pelvic and prostate RT andADT as comparedwith
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